Method of treating obesity with chlorogenic acid

ABSTRACT

The present invention is directed compositions derived from green coffee bean extract and methods for the use and manufacture of such compositions. The compositions of the invention have unique ratios of chlorogenic acids which offer a therapeutic effect in the treatment of a variety of conditions and disorders. Methods for using the compositions of the invention include, but not limited to, methods for treating obesity and methods for regulating serum lipids.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 14/814,494 filed Jul. 30, 2015 which claims priority to provisional application Ser. No. 62/031,135 filed Jul. 30, 2014. The entire contents of these applications are incorporated herein by reference in their entirety for all purposes.

FIELD OF THE INVENTION

The invention generally relates to compositions of chlorogenic acids and methods for their manufacture and use in managing obesity. More particularly, such compositions relate to formulations of chlorogenic acids from green coffee extract.

BACKGROUND

Obesity is a condition manifesting almost directly as a consequence of modern day lifestyle that encompasses sedentary work-culture, high fat, calorie-rich diet, dearth of regular exercise or physical activity, addiction to habit forming substances such as tobacco and alcohol and high day-to-day stress levels. Obesity has reached epidemic proportions globally, with more than 1 billion adults overweight—at least 300 million of them clinically obese—and is a major contributor to the global burden of chronic disease and disability. Ischemic heart disease or cardiovascular diseases are the conditions, often referred to as lifestyle diseases, that have obesity as one of their root causes. Ischemic heart disease is the number one cause of death in the world today, according to a recent World Health Organization (WHO) report that may be found at http://who.int/mediacentre/factsheets/fs310/en/. Cardiovascular diseases (CVDs) have killed nearly 17 million people in the year 2011 which amounts to 3 in every 10 deaths. CVDs are among the top causes of death, in India as well, as per the WHO. The importance of managing obesity is, thus, evident.

Often coexisting in developing countries with under-nutrition, obesity is a complex condition, with serious social and psychological dimensions, affecting virtually all ages and socioeconomic groups. Obesity and being overweight pose a major risk for other serious chronic diseases, including type 2 diabetes, hypertension, and stroke and certain forms of cancer. The health consequences range from increased risk of premature death, to serious chronic conditions that reduce the overall quality of life.

It is, therefore, safe to state that managing obesity would substantially aid in reducing global mortality, increasing life expectancy and increasing quality of life. Dietary changes, exercise and activity, behavioral change, prescription weight-loss medications and weight-loss surgery are the common treatment arms for managing obesity. The treatment method to be undertaken often depends on the preferred choice of an individual undergoing treatment as well as the level of obesity.

The preferred treatment modality for weight loss is dieting and physical exercise. However, due to busy schedules and sedentary lifestyles, following-up with the first two methods seems to be practiced in an irregular manner. Weight loss surgery, on the other hand, is ruled out by a host of the population due to high costs involved. Therefore, there is a gradual shift towards an increase in the use of drugs.

The drugs used for weight loss, generally alter one of the fundamental processes of the human body such as weight regulation by altering appetite, metabolism or absorption of calories. Orlistat is the only anti-obesity medication which is currently approved by the FDA for long term use. It reduces the intestinal fat absorption by inhibiting the pancreatic enzyme lipase. Rimonabant and Sibutramine are the other drugs that had initially been approved for the treatment of obesity, but were banned eventually due to safety concerns. Because of the potential side effects, it is recommended that anti-obesity drugs only be prescribed for obesity where it is hoped that the benefits of the treatment outweigh its risk.

What is needed in the art therefore is a nutrition-based intervention that provides an inexpensive alternative to aid weight loss and weight management. The inventors of the present invention, therefore, envisage a cost-effective and safe herbal composition or a dietary supplement which is used for the management of obesity.

SUMMARY OF THE INVENTION

Some of the objects of the present disclosure are described herein below:

It is an object of the present disclosure to provide a composition for the management of obesity.

It is another object of the present disclosure to provide a composition for the management of obesity, which is cost-effective and non-toxic.

It is yet another object of the present disclosure to provide a composition of CGA-7 Complex isomers from Indian Green coffee bean extract for reducing body weight, removal of abdominal fat tissue, removal BAT, reducing cholesterol levels, improving HDL levels and restoring glucose levels.

It is still another object of the present disclosure to provide a process for the preparation of CGA-7 Complex.

It is yet another object of the present disclosure to provide a method for the treatment and/or prevention of diseases associated with obesity, amongst others.

Other objects and advantages of the present disclosure will be more apparent from the following description which is not intended to limit the scope of the present disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows an LC chromatogram of composition of the invention.

FIG. 2 shows an MS chromatogram of composition of the invention.

FIG. 3 shows the percent reduction of body mass index resulting from the administration of a composition of the invention.

FIG. 4 shows the percent reduction of body mass index resulting from the administration of a composition of the invention.

FIG. 5 shows the percent reduction of waist circumference resulting from the administration of a composition of the invention.

FIG. 6 shows the percent reduction of hip circumference resulting from the administration of a composition of the invention.

FIG. 7 shows the effect of a composition of the invention on lipid profile.

FIGS. 8A and 8B show that weight gain and average feed intake pattern where CGA-7 Complex at 100 and 150 mg/kg was administered decreased weight gain compared to HFD and GCBE groups which was statistically significant. There is no difference in feed intake in between HFD and other treated group.

FIGS. 9A-9E represent changes in liver and adipose tissue weight. CGA-7 Complex at 100 and 150 mg·kg dose inhibited fat deposition in liver, BAT, mesenteric fat, epididymal and perirenal fat compared to HFD and GCBE groups which was statistically significant.

FIGS. 10A-10D show changes in cholesterol, triglyceride (TG), glucose and HDL blood serum level. CGA-7 Complex 100 and 150 mg/kg groups have decreased cholesterol, TG and glucose compared to HFD and GCBE groups which was statistically significant. CGA-7 Complex treated groups have significantly improved HDL level.

FIG. 11 shows the structure of ligand molecules: (1) 3-O-Caffeoylquinic acid; (2) 4-O-Caffeoylquinic acid; (3) 5-O-Caffeoylquinic acid; (4) 5-O-Feruloylquinic acid; (5) 3,4-O-Dicaffeoylquinic acid; (6) 3,5-O-Dicaffeoylquinic acid; (7) 4,5-O-Dicaffeoylquinic acid; and (8) Orlistat.

DETAILED DESCRIPTION

In accordance with one aspect of the present disclosure, there is provided a process for the preparation and use of a composition comprising one or more chlorogenic acids (e.g. CGA-7 Complex). The part plants used for the preparation of the composition of the invention may be fresh and/or dried. Typically, the composition is prepared by obtaining an extract of one or more chlorogenic acids. Such extract can be obtained by processes including, but not limited to, alcoholic, hydro-alcoholic and aqueous extract. Further, the composition is prepared by using techniques selected from the group that includes but is not limited to hot stirring, Soxhlet extraction, percolation, decoction, maceration and supercritical fluid extraction. The solvent used for extraction can be a polar organic solvent and/or a non-polar organic solvent. Solvents suitable for use with the invention include, but are not limited to water, methanol, ethanol, butanol, hexane, acetone, chloroform, petroleum ether and acetonitrile. In one embodiment of the present disclosure, green coffee beans are subjected to extraction to obtain a combination of one or more chlorogenic acids.

The composition may be formulated to attain a particular chlorogenic acid content. The composition may have a total chlorogenic acid content of between about 20-60% w/w. The composition may have a total chlorogenic acid content, by weight, of about 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, as well as any amount intervening these specifically described amounts. The total chlorogenic acid content may be 42.50±2.5 w/w %. The total chlorogenic acid content may be constituted from one or more of 3 CQA, 5 CQA, 4 CQA, 3,4 Di CQA, 3,5 Di CQA, 4,5 Di CQA. The total chlorogenic acid content may contain, for example, a chlorogenic acid content of about 1-15% w/w 3 CQA, about 5-50% w/w 5 CQA, about 1-20% w/w 4 CQA, about 0.5-10% w/w 3,4 Di CQA, about 0.5-10% w/w 3,5 Di CQA, about 0.5-10% w/w 4,5 Di CQA, or combination thereof. The composition may contain 4.1±1.42 w/w % 3 CQA, 28±4.65 w/w % 5 CQA, 6.5±2.25 w/w % 4 CQA, 0.84±0.26 w/w % 3,4 Di CQA, 1.23±0.34 w/w % 3,5 Di CQA, and 1.85±0.42 w/w % 4,5 Di CQA.

In one embodiment of the present invention, the composition comprises a combination of chlorogenic acids. In one non-limiting embodiment, the composition comprises 3-caffeoylquinic acid (3-CQA), 5-caffeoylquinic acid (5-CQA), 4-caffeoylquinic acid (4-CQA), 5-feruloylquinic acids (5-FQA), 3,4 dicaffeoylquinic acids (3,4 di CQA), 3,5 dicaffeoylquinic acids (3,5 di CQA), and 4,5 dicaffeoylquinic acids (4,5 di CQA).

In one non-limiting embodiment, the composition comprises 3-caffeoylquinic acid (3-CQA) at about 7.23%, 5-caffeoylquinic acid (5-CQA) at about 25.43%, 4-caffeoylquinic acid (4-CQA) at about 9.51%, 5-feruloylquinic acids (5-FQA) at about 1.84%, 3,4 dicaffeoylquinic acids (3,4 di CQA) at about 2.79%, 3,5 dicaffeoylquinic acids (3,5 di CQA) at about 1.90%, and 4,5 dicaffeoylquinic acids (4,5 di CQA) at about 3.74%.

The term “about” as used herein refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. In particular embodiments, the terms “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 15%, 10%, 5%, or 1%, or any intervening range thereof.

In accordance with another aspect of the present disclosure, there is provided a process for the preparation of a dosage form comprising the composition of the invention. In accordance with yet another aspect of the present disclosure there is provided a complex mixture for managing obesity that comprises a combination of chlorogenic acids. The phyto-constituents included in the composition of the present disclosure can be in any form that permits an effective dosage for use such as the management of obesity. Suitable forms for administering the composition include, but are not limited to, extracts, granules, powders, semisolids, isolated fractions, oils, solutions, suspensions, emulsions and semisolids. In one embodiment, the composition is a complex mixture obtained from Indian Green coffee bean.

The composition of the present invention may be administered by various routes including but not limiting to topical, oral, buccal, sub-lingual, parenteral, rectal, and inhalation. The composition may be in the form of a dosage form that includes but is not limited to powders, pills, tablets, pellets, capsules, thin films, solutions, sprays, syrups, linctuses, lozenges, pastilles, chewing gums, pastes, vaporizers, suspensions, emulsions, ointments, creams, lotions, liniments, gels, drops, topical patches, buccal patches, injections and the like. Typically, the composition further comprises at least one pharmaceutically acceptable excipient.

The composition of the present invention can be used in any application in which administration of the composition to a subject provides beneficial health effects. Suitable applications for administration of the composition include, but are not limited to, preventing oxidation (antioxidant activity), controlling and/or reducing body weight, controlling and/or reducing body mass index, controlling and/or reducing obesity, management of hyperlipidemic conditions, reducing oxidative stress, maintaining a healthy lipid profile, regulating blood glucose levels, treatment of liver cirrhosis, treatment of atherosclerosis, and treatment bacterial infection. The composition of the invention may be administered to reduce low density lipids. The composition of the invention may be administered to increase high density lipids. The composition of the invention may be administered to reduce low density lipids and increase high density lipids. Significantly, the composition is non-toxic and non-mutagenic.

The phrase “body mass index” as used herein refers to a ratio of height to body weight that is calculated as follows:

${B\; M\; I} = {\frac{{mass}_{kg}}{{height}_{m}^{\; 2}} = {\frac{{mass}_{l\; b}}{{height}_{i\; n}^{\; 2}} \times 703}}$

The terms “obese” and “obesity” as used herein refer to a subject having a body mass index of 30 or higher.

The term “overweight” as used herein refers to a subject having a body mass index of 25 to 29.9.

The term “healthy weight” as used herein refers to a subject having a body mass index of 18.5 to 24.9.

The phrase “treating obesity” as used herein refers to reducing BMI in an obese subject, reducing body fat in an obese subject, or reducing body weight in a subject.

As used herein, the term “controlling” refers to maintaining the state of a condition so as to prevent an increase or decrease in the condition or an increase or decrease in the symptoms of the condition. Controlling may refer to controlling obesity wherein the state of obesity of a subject is maintained such that the body weight or body mass index of a subject is maintained at a level without any appreciable increase in body weight or body mass index.

As used herein, the term “reduce,” “reducing” and the like refer to any measurable decrease in a condition or parameter that results from the administration of the composition of the invention to a subject when compared to the absence of the administration of the composition, such as compared to the administration of a control composition (e.g. a placebo). In some aspects of the invention, administration of a composition of the invention to a subject reduces obesity or body weight in the subject when compared to the administration of a control substance to a subject. In some aspects of the invention, administering the compositions of the invention maintains body weight (i.e. prevents an increase in body weight or an increase in percent body fat).

As used herein, the terms “treatment,” “treating,” and the like, when used in reference to a subject, refer to obtaining a desired pharmacologic and/or physiologic effect, including without limitation achieving a reversal, improvement or elimination of the symptoms of a disease or condition. The effect can be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or can be therapeutic in terms of achieving an improvement or elimination of symptoms, or providing a partial or complete cure for a disease and/or adverse effect attributable to the disease. “Treatment,” as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which can be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; (c) relieving the disease, e.g., causing regression of the disease, e.g., to completely or partially eliminate symptoms of the disease; and (d) restoring the individual to a pre-disease state, e.g., reconstituting the hematopoietic system.

The compositions of the invention can be administered to treat obesity in a subject. The compositions of the invention can be administered to reduce body mass index in an obese subject. The compositions of the invention can be administered to reduce body mass index in an overweight subject. The compositions of the invention may be administered to control or prevent weight gain in a subject. In some aspects of the invention may be administered to maintain or achieve a healthy weight in a subject. The compositions of the invention can be administered to reduce body fat in an obese subject. The compositions of the invention can be administered to reduce body fat in an overweight subject. The compositions of the invention may be administered to control or prevent body fat gain in an obese subject. The compositions of the invention may be administered to control or prevent body fat gain in an overweight subject. The compositions of the invention may be administered to control or prevent body fat gain in a healthy weigh subject.

As used herein, “administer” or “administration” refers to the act of physically delivering a substance as it exists outside the body into a subject. Administration includes all forms known in the art for delivering therapeutic agents, including but not limited to oral, topical, mucosal, injections, intradermal, intravenous, intramuscular delivery or other method of physical delivery described herein or known in the art (e.g., implantation of a slow-release device, such as a mini-osmotic pump to a subject; liposomal formulations; buccal; sublingual; palatal; gingival; nasal; vaginal; rectal; intra-arteriole; intraperitoneal; intraventricular; intracranial; or transdermal). The compositions described herein can be administered intravenously.

The compositions of the invention may be administered in an effective amount. The phrase an “effective amount” as used herein refers to an amount of a composition of the invention that is sufficient to achieve the effect for which the composition is administered (e.g., to maintain or reduce obesity).

The terms “subject,” “patient,” “subject in need thereof,” and “patient in need thereof” are herein used interchangeably and refer to mammal, including humans. Subjects may also be cattle, sheep, goats, pigs or other animals used in animal husbandry. In a preferred embodiment the subject is a human. The subject can be a human suffering from obesity or having an unhealthy body weight.

The composition of the invention may be obtained from any source material capable of providing the chlorogenic acids disclosed herein. The compositions of the invention can be obtained from green coffee bean material. In one non-limiting embodiment of the invention, the composition is derived from Indian green coffee bean material. The term “green coffee bean” as used herein refers to unroasted mature or immature coffee beans. Green coffee beans can be processed by wet or dry methods for removing the outer pulp and mucilage, and can have an intact wax layer on the outer surface. When immature coffee beans are immature, they are green. When mature, they have a brown to yellow or reddish color, and typically weigh 300 to 330 mg per dried coffee bean. The compositions of the invention may comprise green coffee extract as an extract of unroasted, green coffee beans. The compositions of the invention may be obtained from the green coffee bean. The compositions of the invention may be obtained from the outer pulp (mucilage) of the bean. The compositions of the invention may be obtained from the green coffee bean. The compositions of the invention may be obtained from a combination of the green coffee bean and the pulp of the coffee bean.

The present disclosure is further described in the light of the following non-limiting examples which are set forth for illustration purpose only and not to be construed for limiting the scope of the present invention.

Example 1: Process for Preparation of the Complex Mixture of the Present Disclosure (CGA-7 Complex)

100 kg of Green coffee bean was stacked in a vertical 1.0 KL extractor. The bottom of the extractor comprised of a perforated plate on which filtration cloth was fixed. About six bed volumes of 70% v/v ethyl alcohol was added. Extraction was continued at 75-78° C. about 7-8 hrs with continuous circulation of extract with transfer pump. After completion of extraction, the extract was filtered through 5 micron SS candle filter and clear extract was collected in a cleaned receiver tank. The bed was re-extracted by adding 4 bed volumes of 70% ethyl alcohol 3 more times and temperature was maintained at 75-78° C. about 7-8 hrs. All the extracts were collected in a receiver tank and combined extract was concentrated in a reactor under vacuum at 80±5° C. till extract was free from ethyl alcohol. Solution was made up to the TDS to 20-25 w/v % with de-ionized water.

The above extract solution was passed through 500 Liter of XAD-4 resin and the extract was loaded through the resin at the rate of 2-3 bed volumes/hour. The resin was washed with 2-3 bed volumes of de-ionized water at the rate of 2-3 bed volumes/hour. The extract was eluted with 2-3 bed volumes of 70 v/v % ethyl alcohol at the rate of 2-3 bed volumes/hour. The eluent was concentrated in a reactor at 80±5° C. till free from alcohol. The solution TDS was made up to 25-30 w/v % and spray dried at 215±5° C. to obtain the complex mixture of CGA-7.

The composition of the chlorogenic acid isomers was determined by the HPLC method and the following results were obtained:

TABLE 1 Peak Table showing Types of Chrologenic acids Ret. Height Peak Name Time Area Area % Height % 1 3 CQA 3.209 1904533 12.529 395880 13.745 2 5 CQA 5.017 7126683 46.883 1394953 48.431 3 4 CQA 5.218 2612578 17.187 521622 18.110 4 5 FQA 7.489 703664 4.629 136587 4.742 5 3,4 Di CQA 11.049 941037 6.191 162285 5.634 6 3,5 Di CQA 11.549 694548 4.569 111103 3.857 7 4,5 Di CQA 12.659 1218027 8.013 157843 5.480 Total 15201070 100 2880273 100

The fingerprint of composition of the chlorogenic acid isomers was determined by the LC-MS/MS method and the following results were obtained:

Example 2: In-Vitro Studies of the Complex Mixture (CGA-7 Complex) Antioxidant Assay: DPPH Scavenging Assay

The free radical scavenging capacity of CGA-7 Complex was determined using DPPH scavenging assay (Sarojini et al., 2011). DPPH solution was prepared in 95% methanol. Freshly prepared DPPH solution was taken in test tubes and coffee preparations were added and incubated for 20 min. The absorbance was read at 515 nm using a spectrophotometer. A blank was prepared containing the same volume of reaction mixture without any tested samples. The percentage of scavenging was calculated using the formula:

% Scavenging=Ac−As/Ac×100

Where AC was the absorbance of the control (blank without extract) and As was the absorbance in the presence of the extract.

Metal Chelating Activity

The chelating of ferrous ions by the extracts was estimated by the following method. CGA-7 Complex was added to a solution of 2 mM FeCl2 (0.05 ml), the reaction was initiated by the addition of 5 mM ferrozine (0.2 ml). The mixture was then shaken vigorously and kept for 10 min at room temperature [26]. Absorbance of the solution was measured at 562 nm. The percentage of inhibition of ferrozine-Fe2+ complex formation was calculated as follows.

Chelating rate (%)=Ac−As/Ac×100

Where AC was the absorbance of the control (blank without extract) and As was the absorbance in the presence of the extract.

Superoxide Anion Scavenging Activity

Superoxide anion scavenging activity of CGA-7 Complex was measured according to the method of (Nishimiki et al., 1972). All the solutions in this experiment were prepared using phosphate buffer (pH 7.4). 1 ml of NBT (156 μM) was added to 1 ml of NADH (468 μM) and 3 ml of test samples to all test tubes. The reaction was started by adding 100 ml of PMS (60 μM) and the mixture was incubated at 25° C. for 5 min followed by measurement of absorbance at 560 nm. The percentage of scavenging was calculated using the formula:

% Scavenging=Ac−As/Ac×100

Where AC was the absorbance of the control (blank without extract) and As was the absorbance in the presence of the extract.

Reducing Power Assay

The reductive ability of CGA-7 Complex was determined. The test samples were mixed with 2.5 ml of 0.2 M phosphate buffer (pH 6.6) and 2.5 ml of 1% potassium ferricyanide [K3Fe(CN)6]. Reaction mixture was incubated at 50° C. for 20 min, 2.5 ml of 10% trichloroacetic acid was added, then centrifuged (650 rpm at room temperature) for 10 min. The upper layer solution (2.5 ml) was mixed with 2.5 ml of distilled water and 0.5 ml of 0.1% FeCl₃. Absorbance was measured at 700 nm. Higher the absorbance at 700 nm indicates higher reducing power ability (Oyaizu, 1986).

Total Antioxidant Activity

The phosphomolybdenum method is based on the reduction of Mo (VI) to Mo (V) by the antioxidant compound and the formation of a green phosphate/Mo (V) complex with a maximal absorption at 695 nm. The antioxidant activity of the test sample will be determined by the phosphomolybdenum method as described by Prieto et al., (1999). Briefly, 0.3 ml of test sample was combined with 3 ml of reagent solution (0.6M sulfuric acid, 28 mM sodium phosphate and 4 mM ammonium molybdate). The reaction mixture was—incubated at 95° C. for 90 min and cooled to room temperature. The absorbance of the solution was measured at 695 nm against blank. The total antioxidant capacity is expressed as the number of equivalents of ascorbic acid (AAE).

Results:

Sample name: CGA-7 Complex

TABLE 2 In-vitro assays of CGA-7 Complex Superoxide scavenging DPPH scavenging assay assay Metal chelating Conc Conc Conc in Absorbance % in Absorbance % in Absorbance % μg/ml @517 nm inhibition μg/ml @560 nm inhibition μg/ml @562 nm inhibition Blank 1.801 Blank 0.337 Blank 0.702 100 μg 0.886 50.81 100 μg 0.110 67.36 100 μg 0.726 −3.42 1.007 44.09 0.102 69.73 0.739 −5.27 0.985 45.31 0.120 64.39 0.746 −6.27 0.967 46.31 0.123 63.50 0.734 −4.56 0.976 45.81 45.97 66.25 −4.88 Total antioxidant assay Reducing power assay Conc in Absorbance Conc in Absorbance μg/ml @695 nm AAE (μg) μg/ml @700 nm AAE (μg) 100 μg 0.078 14.78 100 μg 0.545 58.55 0.078 14.80 0.590 63.37 0.080 14.95 0.598 64.16 0.074 14.50 0.560 60.09 0.078 14.80 0.555 59.63 14.76 61.16

Example 3: In-Vivo Studies of CGA-7 Complex

A] Acute Oral Toxicity Study in Rats with CGA-7 Complex

Single-dose oral toxicity of the CGA-7 Complex was evaluated in albino Wistar rats. A limit test was performed in which female rats received a single oral administration of the CGA-7 Complex at a dose of 2000 mg/kg body weight. Following dosing, the limit test rats were observed daily and weighed weekly. A gross necropsy examination was performed on all limit test animals at the time of scheduled euthanasia (day 14). No mortality occurred during the duration of the limit test. Further, no significant gross internal findings were observed at necropsy on study day 14.

Under the experimental conditions described, the acute oral LD₅₀ of CGA-7 complex was estimated to be greater than 2000 mg/kg in the rat.

B] Repeated Dose 90 Days Toxicity with CGA-7 Complex

Repeated dose 90 day oral toxicity study was performed with CGA-7 complex in both male and female Wistar rats followed by 14 day recovery period to determine target organ toxicity. No observed adverse effect level (NOAEL) and reversibility of signs of toxicity after recovery period.

Results of acute oral toxicity studies in Wistar albino rats indicated the acute oral LD₅₀ of CGA-7 complex was estimated to be greater than 2000 mg/kg in the rats. Based on the above results; three doses were selected as 250, 500 and 1000 mg/kg b.w. Oral route of administration was selected because it is the proposed therapeutic route.

Observations

Clinical signs of toxicity: No clinical signs of toxicity were observed in all male and female groups of animals throughout the dosing period of 90 days and during the recovery period of 14 days.

Mortality: All the male and female groups of animals survived throughout the dosing period of 90 days and during the recovery period of 14 days.

Body Weight: Body weights were recorded 0 to 90 days for all groups and continued for day 97 and 104 for reversal groups.

Body weight gain: A significant decrease in body weight gain was seen in all groups of animals treated with CGA-7 Complex at 250, 500 and 1000 mg/kg b.w. in both males and females when compared with control. During the reversal period the animals also showed a significant decrease in body weight gain to normal when compared with control reversal group.

Food Intake: No effect of treatment in all groups of animals was noted on food consumption throughout the dosing period of 90 days and during the recovery period of 14 days.

Functional observations: The functional observational parameters performed showed no changes in all groups of male and female animals.

Blood Analysis

Hematology: No significant changes were observed in all groups of male and female animals when compared with those of respective control groups. No dose dependent changes were seen.

Clinical Chemistry: No significant changes were observed in all groups of males and females when compared with those of respective control groups.

Urine analysis: No changes were noted in urine analysis of all groups of male and female animals when compared with those of respective control groups.

Sacrifice and Pathology

Relative Organ weight: No significant changes were observed in all groups of male and female animals when compared with those of respective control groups. No dose dependent changes were observed.

Gross pathology: No gross changes were observed in all groups of male and female animals.

Histopathological studies: No changes were seen in brain, liver, heart, spleen, kidneys, ovaries, large intestine and adrenal glands in animals treated with CGA-7 Complex 1000 mg/kg b.w. when compared with control.

Conclusion: Based on the above findings, the no observed adverse effect level (NOAEL) of CGA-7 complex was found to be 1000 mg/kg.b.w. for both female and male Wistar rats when given orally for 90 days followed by 14 day recovery period.

C] Anti-Obesity Activity of the CGA-7 Complex:

Objective: The objective was to investigate the effect of the CGA-7 complex against high fat diet fed rats.

Procedure:

Model: High fat diet in rats

Composition of high fat diet

25% Lard

5% Soyabean oil

5% Starch

65% Normal commercial available rat feed

Male Wistar rats were divided into six groups with six animals in each group.

TABLE 3 Specifications of groups S. NO Group Test substance 1 Group I Normal feed + Vehicle (distilled water) 2 Group II High fat diet + Vehicle (distilled water) 3 Group III High fat diet + Standard drug (orlistat 30 mg/kg) 4 Group IV High fat diet + CGA 7 Complex (50 mg/kg) 5 Group V High fat diet + CGA 7 Complex (100 mg/kg) 6 Group VI High fat diet + CGA 7 Complex (150 mg/kg)

Parameters Evaluated

Body weight was measured once every 2 days. Food intake was measured daily for 42 days.

On day 43, all the animals were kept overnight fasting before sacrifice. Blood was collected by puncturing the retro orbital plexus. Serum was separated by centrifugation at 3000 rpm for 10 minutes.

Serum was estimated for glucose, cholesterol, triglycerides and HDL. LDL and atherogenic index were also calculated. Liver, mesenteric, brown adipose tissue (BAT), left and right perirenal fat pads, left and right epididymal pads were isolated and weighed. Liver was isolated and estimated for liver triglycerides and cholesterol levels.

Statistical Analysis

Data were expressed as mean±SEM & analyzed by one way ANOVA followed by Dunnett's t test using graph pad prism version 5. Differences were considered significant at a p value of <0.05.

Results

TABLE 4 Effect of CGA 7 Complex on body weight in male rats Groups Final weight Initial weight Difference in body weight Group I 220.5 ± 2.54 150.1 ± 2.67 68.41 ± 1.18 Group II 230.3 ± 5.57 137.0 ± 0.32 112.0 ± 4.51***^(a) Group III 218.4 ± 2.65 130.3 ± 0.56 88.01 ± 3.68***^(b) Group IV 211.7 ± 2.42 136.1 ± 0.62 75.65 ± 3.44***^(b) Group V 229.7 ± 1.94 163.8 ± 2.33 65.88 ± 2.14***^(b) Group VI 199.0 ± 2.08 138.4 ± 1.07 60.63 ± 2.89***^(b) Values are expressed in terms of SEM ± Mean. Data were analyzed by one way ANOVA followed by Dunnett's t test. Number of animals in each group n = 6. ^(a)Comparison made with control group. ^(b)Comparison made with high fat diet group. ***P < 0.001.

TABLE 5 Effect of CGA 7 Complex on average food intake in male rats Groups Average food intake g/rat Group I 14.93 ± 0.77 Group II  8.26 ± 0.51***^(a) Group III  8.54 ± 0.40^(nsb) Group IV  7.78 ± 0.45^(nsb) Group V  8.96 ± 0.45^(nsb) Group VI  6.98 ± 0.35^(nsb) Values are expressed in terms of SEM ± Mean. Data were analyzed by one way ANOVA followed by Dunnett's t test. Number of animals in each group n = 6. ^(a)Comparison made with control group. ^(b)Comparison made with high fat diet group. ***P < 0.001 ^(ns)non significant.

TABLE 6 Effect of CGA 7 Complex on liver organ weight, mesenteric, brown adipose tissue (BAT), perirenal fat pads and epididymal fat pad. Epididymal fat Mesenteric Peri renal fat pad tissue pad Groups Liver fat BAT Right Left Right Left Group I 3.87 ± 0.18 0.59 ± 0.06 0.06 ± 0.004 0.30 ± 0.02 0.28 ± 0.01 0.35 ± 0.03 0.38 ± 0.01 Group II 4.50 ± 0.19*^(a) 1.31 ± 0.12***^(a) 0.24 ± 0.01***^(a) 1.22 ± 0.12***^(a) 0.85 ± 0.05***^(a) 0.58 ± 0.04***^(a) 0.60 ± 0.02***^(a) Group III 3.47 ± 0.11***^(b) 0.98 ± 0.03*^(b) 0.19 ± 0.01**^(b) 0.65 ± 0.04*^(b) 0.61 ± 0.05*^(b) 0.48 ± 0.01*^(b) 0.50 ± 0.01**^(b) Group IV 3.56 ± 0.10***^(b) 1.01 ± 0.07*^(b) 0.20 ± 0.01*^(b) 0.52 ± 0.03***^(b) 0.54 ± 0.03***^(b) 0.44 ± 0.02**^(b) 0.46 ± 0.03***^(b) Group V 3.57 ± 0.12***^(b)  1.0 ± 0.04*^(b) 0.17 ± 0.01***^(b) 0.43 ± 0.02***^(b) 0.41 ± 0.03***^(b) 0.41 ± 0.02***^(b) 0.38 ± 0.02***^(b) Group VI 3.39 ± 0.10***^(b)  1.0 ± 0.07*^(b) 0.17 ± 0.01***^(b) 0.36 ± 0.02***^(b) 0.38 ± 0.03**^(b) 0.40 ± 0.03***^(b) 0.37 ± 0.01***^(b) Data were analyzed by one way ANOVA followed by Dunnett's t test. Number of animals in each group n = 6. ^(a)Comparison made with control group. ^(b)Comparison made with high fat diet group. ***P < 0.001 **P < 0.01 *P < 0.05.

TABLE 7 Effect of CGA 7 Complex on serum glucose, total cholesterol, triglyceride, HDL-c and LDL-c levels (mg/dL) Total Groups Glucose cholesterol Triglyceride HDL-c LDL-c Group I  84.53 ± 4.62 56.00 ± 1.44 70.56 ± 3.59 24.56 ± 0.88 17.33 ± 1.78 Group II 131.00 ± 5.88***^(a) 78.08 ± 1.40***^(a) 137.7 ± 7.95***^(a) 16.73 ± 0.59***^(a) 33.81 ± 2.11***^(a) Group III  109.7 ± 3.93**^(b) 63.38 ± 0.95***^(b) 77.63 ± 4.27***^(b) 20.47 ± 1.08*^(b) 27.39 ± 1.07^(nsb) Group IV  89.29 ± 2.79***^(b) 62.23 ± 1.74***^(b) 86.32 ± 5.06***^(b) 20.22 ± 0.82*^(b) 25.12 ± 2.33*^(b) Group V  87.63 ± 3.28***^(b) 58.16 ± 2.18***^(b) 75.36 ± 4.17***^(b) 20.50 ± 1.10*^(b) 22.59 ± 2.67**^(b) Group VI  86.23 ± 3.50***^(b) 45.20 ± 2.37***^(b) 62.98 ± 2.97***^(b) 20.51 ± 0.94*^(b) 12.09 ± 2.31***^(b) Data were analyzed by one way ANOVA followed by Dunnett's t test Number of animals in each group n = 6. ^(a)Comparison made with control group. ^(b)Comparison made with high fat diet group. ***P < 0.001 **P < 0.01 *P < 0.05

TABLE 8 Effect of CGA 7 Complex on atherogenic index Group Atherogenic Index Group I 1.30 ± 0.10 Group II 3.72 ± 0.22***^(a) Group III 2.20 ± 0.20***^(b) Group IV 2.18 ± 0.15***^(b) Group V 1.91 ± 0.23***^(b) Group VI 1.22 ± 0.14***^(b) Data were analyzed by one way ANOVA followed by Dunnett's t test. Number of animals in each group n = 6. ^(a)Comparison made with control group. ^(b)Comparison made with high fat diet group. ***P < 0.001

TABLE 9 Effect of CGA 7 Complex on liver cholesterol & triglyceride levels Group liver cholesterol liver triglycerides Group I 23.92 ± 1.50 50.51 ± 2.16 Group II 69.53 ± 2.54***^(a) 87.93 ± 3.56***^(a) Group III 49.66 ± 3.28***^(b) 64.64 ± 3.44***^(b) Group IV 48.48 ± 3.58***^(b) 57.68 ± 4.25***^(b) Group V 44.61 ± 4.45***^(b) 59.91 ± 2.73***^(b) Group VI 28.53 ± 2.69***^(b) 36.04 ± 4.42***^(b) Data were analyzed by one way ANOVA followed by Dunnett's t test. Number of animals in each group n = 6. ^(a)Comparison made with control group. ^(b)Comparison made with high fat diet group. ***P < 0.001 **P < 0.01 *P < 0.05

Conclusion

The CGA 7 complex reduces body weight, removes abdominal fat tissue, removes brown adipose tissue, reduces cholesterol levels, improves HDL c levels, and restores glucose levels.

Example 4: Clinical Evaluation of CGA-7 Complex of the Present Disclosure

A Prospective, Randomized, Double blind, Placebo controlled clinical trial to evaluate efficacy and safety of CGA-7 Complex in reducing the bodyweight in obese patients.

The subjects had to complete 5 visits including 1 screening visit and 4 scheduled visits; i.e., screening visit, Visit 1 (baseline)—Day 1, Visit 2—Day 14±3, Visit 3—Day 28±3, Visit 4—Day 56±3. The screening visit consisted of patient consent form, multiple laboratory tests, physical examinations, anthropometric measurements and understands inclusion/exclusion criteria. After screening, subjects were randomized and assigned to Group A and Group B for CGA-7 Complex and placebo treatment respectively. Primary outcomes reduction in body weight and BMI on visit 2, visit 3 and visit 4 were recorded. Baseline quality of life assessment (SF-36) was also carried out. During visit 2 & 3 the anthropometric measurements, physical examination, adverse events, and concomitant medications if any were recorded. In final visit, physical examinations, anthropometric measurements, lipid profile, fasting blood glucose, HbA1c, quality of life assessment, adverse events, concomitant medications were recorded. The unused tablets were collected back.

The effect of CGA-7 Complex was validated in the absence of exercise, walking and without diet restrictions during the course of the trial.

Sample Size

A total of 42 patients were screened and among them 30 were included in the study as per inclusion criteria. Subjects were randomized and an equal number of subjects were assigned in CGA-7 Complex treatment group A and placebo treatment group B. Two patients were dropped out from both groups without any information during the study.

Statistical Analysis

Paired t-test was used to measure the change from the baseline. ANOVA was used in order to observe the changes in the various parameters after the follow up visits scheduled, followed by appropriate post-hoc test.

Results Body Weight

As shown in FIG. 3, in the CGA-7 Complex treated group, baseline mean body weight was 80.6±10 which was reduced up to 76.57±10.2 on day 56. Whereas in the placebo treated group, on day 56 weight reduction was negligible compared to baseline mean body weight.

There was a 5% reduction in body weight observed in CGA-7 Complex treated group compared to baseline, which is significant compared to the placebo treated group. In the placebo treated group only 0.9% of reduction was seen in body weight compared to baseline.

BMI

As shown in FIG. 4, mean BMI of the CGA-7 Complex treated group at baseline was 30.53±0.62 which was significantly reduced to 28.97±0.73 on last the visit. The same was found to be slightly decreased in the placebo treated subjects.

The CGA-7 Complex treated group has shown 5.10% reduction in BMI on day 56 whereas it was only 0.9% in the placebo treated group.

Waist Circumference

As shown in FIG. 5, there was a significant reduction in waist circumference on day 56 in the CGA-7 Complex treated group compared to baseline which was 103.28±4.14 and 99.85±5.36, respectively. Whereas, the placebo treated group had shown negligible improvement in waist circumference.

Hip Circumference

As shown in FIG. 6, hip circumference was significantly improved in the CGA-7 Complex treated group compared to the placebo treated group. The baseline mean hip circumference was 105.85±4.88 which was reduced to 104.78±4.88 after 56 days treatment with CGA-7 Complex.

1.01% of reduction was seen in the CGA-7 Complex treated group which was only 0.13% in the placebo treated group.

Lipid Profile

As shown in FIG. 7, the results collected have shown that CGA-7 Complex has significant improvement in lipid profile. The mean triglyceride level at baseline was 151±39.39 which decreased significantly to 134.43±38.15 at Day 56 after treatment with CGA-7 Complex and the percentage of triglyceride levels reduced compared to baseline was 10.97%.

The mean total cholesterol value at baseline was 172.07±32.99 which decreased to 162.36±32.10 at Day 56 after treatment with CGA-7 Complex and the percentage of total cholesterol levels reduced compared from baseline to visit 4 was 5.64%.

The mean HDL level at baseline was 37.91±8.29 which increased significantly to 42±7.75 at Day 56 after treatment with CGA-7 Complex and the percentage of HDL level increased was 10.78%.

The mean LDL level at baseline was 103.96±27.18 which decreased significantly to 88.5±29.62 at Day 56 after treatment with CGA-7 Complex and the percentage of LDL levels reduced compared from baseline to visit 4 was 14.87%.

The mean VLDL level at baseline was 30.2±7.87 which decreased significantly to 26.88±7.63 at Day 56 after treatment with CGA-7 Complex and the percentage of VLDL levels reduced compared from baseline to visit 4 was 10.99%.

The results collected have shown that placebo has less improvement in lipid profile. Triglyceride level was slightly decreased compared from baseline to visit 4. The baseline triglyceride value was 150.71±45.96 decreased to 149.71±45.86 at Day 56 after treatment with placebo and the percentage of triglyceride level reduced compared from baseline to visit 4 was 0.7%.

The total cholesterol level has been slightly decreased compared from baseline to visit 4. The baseline total cholesterol value was 174.21±32.03 decreased to 173.57±31.95 at Day 56 after treatment with placebo and the percentage of total cholesterol level reduced compared from baseline to visit 4 was 0.4%.

The mean HDL level showed no change compared from baseline to visit 4. The baseline HDL value was 36.14±7.26 and 36.79±6.92 at Day 56 after treatment with placebo.

The mean LDL slightly decreased compared from baseline to visit 4. The baseline LDL value was 107.93±27.03 decreased to 106.84±26.88 at Day 56 after treatment with placebo. The percentage of LDL level reduced compared from baseline to visit 4 was 1.0%.

The mean VLDL level was slightly decreased compared from baseline to visit 4. The baseline VLDL value was 28.13±11.79 decreased to 29.94±9.17 after treatment with placebo and the percentage of total VLDL level reduced compared from baseline to visit 4 was 6.3%.

CGA-7 Complex is statistically significant in reducing triglycerides, cholesterol, LDL and VLDL compared to placebo.

CGA-7 Complex was statistically significant in increasing HDL compared to placebo. Overall, CGA-7 Complex exhibited significant reduction in triglycerides, cholesterol and LDL levels and significantly increased HDL levels.

TABLE 10 Effect of CGA-7 Complex on body weight, BMI, Waist and hip circumference, serum triglycerides, cholesterol, LDL and VLDL S.N. Parameters Visit 1 Visit 4 Difference % decrease 1 Body weight (kg)  80.6 ± 10 76.57 ± 10.2 4.03 5.00 2 Body mass index (BMI kg/m²)  30.53 ± 0.62 28.97 ± 0.73 1.56 5.10 3 Waist circumference (cm) 103.28 ± 4.14 99.85 ± 5.36 3.43 3.32 4 Hip circumference (cm) 105.85 ± 4.88  104.78 ± 4.88  1.07 1.01 5 Triglycerides (mg/dL)   151 ± 39.39 134.43 ± 38.15 16.57 10.97 6 Cholestrol (mg/dL) 172.07 ± 32.99 162.36 ± 32.10 9.71 5.64 7 LDL (mg/dL) 103.96 ± 27.18  88.5 ± 29.62 15.46 14.87 8 VLDL (mg/dL)  30.2 ± 7.87 26.88 ± 7.63 3.32 10.99 Values are expressed in terms of Mean ± SD

TABLE 11 Effect of CGA-7 Complex on serum HDL S N. Parameters Visit 1 Visit 4 Difference % increase 1 HDL(mg/dL) 37.91 ± 8.29 42 ± 7.75 4.09 10.78 Values are expressed in terms of Mean ± SD

TABLE 12 Effect of placebo on body weight, BMI, waist and hip circumference, serum triglycerides, cholesterol, LDL and VLDL % S.N. Parameters Visit 1 Visit 4 Difference decrease 1 Body weight (kg)  74.03 ± 9.7 73.39 ± 9.4  0.64 0.864 2 Body mass index (BMI kg/m²)  31.01 ± 1.10 30.73 ± 1.18 0.29 0.90 3 Waist circumference (cm) 100.85 ± 5.89 100.57 ± 4.81  0.28 0.27 4 Hip circumference (cm) 104.92 ± 7.19 104.78 ± 5.02  0.14 0.13 5 Triglycerides (mg/dL) 150.71 ± 45.96 149.71 ± 45.86 1 0.7 6 Cholestrol (mg/dL) 174.21 ± 32.03 173.57 ± 31.95 0.64 0.4 7 LDL (mg/dL) 107.93 ± 27.03 106.84 ± 26.88 1.1 1.01 8 VLDL (mg/dL)  28.13 ± 11.79 29.94 ± 9.17 1.81 6.4 Values are expressed in terms of Mean ± SD

TABLE 13 Effect of placebo on serum HDL S. N. Parameters Visit 1 Visit 4 Difference % increase 1 HDL(mg/dL) 36.14 ± 7.26 36.79 ± 6.92 0.65 1.7 Values are expressed in terms of Mean ± SD

Conclusion: CGA-7 complex is effective in reducing body weight, reducing BMI, hip and waist circumferences, improving lipid profile by increasing HDL serum levels and decreasing triglycerides, cholesterol and LDL serum levels, and is safe with no unwanted effects.

Example 5—CGA7 Complex is Superior to Coffee Bean Extract in the Management of Obesity, Serum Cholesterol, Triglyceride, HDL and Glucose Levels

Obesity is a disarray of energy balance and primarily considered as a disorder of lipid metabolism. Obesity and the comorbidities associated with obesity remain a global health problem. It is one of the major public health problems in the world because of its association with an increased risk of various chronic diseases, including cardiovascular diseases, type 2 diabetes, hypertension, dyslipidemia and cancers. Recent estimates in the USA indicate that approximately one-third of the adult population is obese. World Health Organization (WHO) assigns obesity as global epidemic. Globally, approximately 1.6 billion adults are overweight and at least 400 million adults are obese. Further WHO projects that by 2015 approximately 2.3 billion people will be overweight and more than 700 million will be obese.

Coffee is widely used as a beverage all over the world. It has numerous health benefits against obesity, metabolic disorders like type 2 diabetes. The main active constituent of coffee is chlorogenic acids with different isomers present in it. Chlorogenic acid is highly antioxidant and provides protection against liver cirrhosis, atherosclerosis, bacterial infection, and obesity. CGA-7 Complex contains more than 52% of seven different isomers of chlorogenic acid, extracted from the green coffee bean. Several in vitro and in vivo study support that chlorogenic acid has antiobesity activity.

With respect to this, CGA-7 complex containing more than 52% of chlorogenic acid (Proprietary extract of Coffea arabica from VIDYA HERBS PVT LTD) was evaluated against high fat fed S.D. male rats in comparison with green coffee bean extract.

Objective

To investigate the role of CGA-7 Complex proprietary herbal extract of Coffea arabica from VIDYA HERBS against high fat diet fed S.D. male rats compared to green coffee bean extract (GCBE).

Materials and Methods

-   -   Material: CGA-7 Complex     -   Model: High fat diet (HFD) in S.D rats     -   Composition of high fat diet: −200 g of fat/kg (170 g of lard         oil+30 g of corn oil) and 1% cholesterol.

TABLE 14 Grouping of animals Group Treatment Dose (mg/kg, orally) I Control + Vehicle Distilled water 10 ml/kg II HFD + Vehicle Distilled water 10 ml/kg III HFD + GCBE 100 mg/kg IV HFD + CGA-7  50 mg/kg V HFD + CGA-7 100 mg/kg VI HFD + CGA-7 150 mg/kg

36 male S.D rats were divided into 6 groups each containing six animals. Normal rat chow diet was fed to group-1 for 42 days. HFD was fed to group 2-6 for 42 days. Respective treatment was given to all groups for 42 days as described in table.

Parameters Evaluated:

Body weight was measured once every 2 days. Food intake was measured daily for 42 days.

On day 43, all the animals were kept fasting overnight before sacrifice. Blood was collected by puncturing the retro orbital plexus. Serum was separated by centrifugation at 3000 rpm for 10 minutes.

Serum was estimated for glucose, cholesterol, triglycerides and HDL.

Liver, mesenteric, brown adipose tissue (BAT), left and right perirenal fat pads, left and right epididymal pads were isolated and weighed.

Statistical Analysis: Data were expressed as mean±SEM & analyzed by one way ANOVA followed by Dunnett's t test using graph pad prism version 5. Differences were considered significant at a p value of <0.05.

Results

Values are expressed in terms of SEM±Mean. Data were analyzed by one way ANOVA followed by Dunnett's t test. Number of animals in each group n=6. ^(a)Comparison made with control group.^(b) Comparison made with high fat diet group.***P<0.001, **P<0.01

TABLE 15 Effect of CGA-7 Complex on body weight in male rats Control + Vehicle 293.8 ± 1.23 145.9 ± 0.79 147.9 ± 1.09 HFD + Vehicle 360.0 ± 1.21 143.6 ± 0.62 216.3 ± 1.61***^(a) HFD + GCBE 345.7 ± 5.06 144.1 ± 0.61 201.7 ± 4.49**^(b) (100 mg/kg) HFD + CGA-7 346.5 ± 3.22 146.1 ± 0.50 200.3 ± 3.51**^(b) (50 mg/kg) HFD + CGA-7 311.3 ± 2.27 144.1 ± 0.99 167.2 ± 3.02***^(b) (100 mg/kg) HFD + CGA-7 304.2 ± 1.81 145.1 ± 1.08 159.1 ± 2.30***^(b) (150 mg/kg)

TABLE 16 Effect of CGA-7 Complex on average feed intake Group Treatment Feed intake (g/per rat) I Control + Vehicle 24.05 ± 0.13 II HFD + Vehicle 17.15 ± 0.08***^(a) III HFD + GCBE (100 mg/kg) 17.88 ± 0.35*^(b) IV HFD + CGA-7 (50 mg/kg) 17.48 ± 0.08 V HFD + CGA-7 (100 mg/kg) 17.75 ± 0.10 VI HFD + CGA-7 (150 mg/kg) 17.34 ± 0.07

TABLE 17 Effect of CGA-7 Complex on liver organ weight, mesenteric, brown adipose tissue (BAT), perirenal fat pads and epididymal fat pad Liver (per Mesentric Epididymal Perirenal Group Treatment 100 g) BAT (per 100 g) fat (per 100 g) Fat (per 100 g) Fat (per 100 g) I Control + 2.688 ± 0.07 0.04 ± 0.002 0.57 ± 0.07 0.44 ± 0.06 0.36 ± 0.07 Vehicle II HFD + 6.467 ± 0.12***^(a) 0.15 ± 0.001***^(a) 1.81 ± 0.03***^(a) 1.94 ± 0.02***^(a) 2.48 ± 0.01***^(a) Vehicle III HFD + 5.832 ± 0.17*^(b) 0.12 ± 0.002*^(b) 1.55 ± 0.01**^(b) 1.69 ± 0.02**^(b) 2.09 ± 0.06**^(b) GCBE (100 mg/kg) IV HFD + 5.598 ± 0.19**^(b) 0.12 ± 0.004*^(b) 1.54 ± 0.06**^(b) 1.66 ± 0.02**^(b) 2.07 ± 0.07**^(b) CGA- 7 (50 mg/kg) V HFD + 4.115 ± 0.19***^(b) 0.08 ± 0.013***^(b) 1.13 ± 0.08***^(b) 1.21 ± 0.09***^(b) 1.14 ± 0.14***^(b) CGA- 7 (100 mg/kg) VI HFD + 3.298 ± 0.17***^(b) 0.06 ± 0.001***^(b) 0.99 ± 0.01***^(b) 1.18 ± 0.03***^(b) 0.98 ± 0.07***^(b) CGA- 7 (150 mg/kg)

Green coffee bean extract is well tolerated as an anti-obesity agent and widely used for the same. Chlorogenic acid is the chief pharmacological active constituent of green coffee bean. There is lack of scientific evidences of role of chlorogenic acid in obesity management, lipid metabolism. CGA-7 Complex mainly contains more than 52% of seven isomers of chlorogenic acids. The effect of CGA-7 Complex has been investigated in high fat diet induced obese S.D male rats by comparing it with green coffee bean extract.

This in vivo study revealed that CGA-7 Complex at the dose of 100 mg/kg and 150 mg/kg has shown 25.3% and 26.4% reduction in body weight gain respectively which was statistically significant compared to GCBE treated group (6.7%). CGA-7 Complex treated groups have also lowered brown adipose and white adipose tissue weight extensively compared to the GCBE treated group.

Visceral adipose tissue discharges plenty of free fatty acids (FFA) and cytokines/hormones into the veins. Further these FFA are transported to the liver where they interact with hepatocytes and various immune cells. It is also believed that body weight and adipose tissue weights are positively correlated with leptin and insulin levels. Cho et al observed that plasma leptin and insulin levels were high in HFD treated group which were significantly lowered by chlorogenic acid supplementation.

Due to leptin resistance, there is an increase in FFA in adipose tissue and liver. When FFA is converted to triglycerides it causes fatty liver by increased lipogenesis and results in hyperinsulinemia and decreased FFA oxidation. De sotillo and Hadley state that chlorogenic acid improves glucose tolerance and decreases plasma and hepatic lipids without changing triglyceride levels in adipose tissue of Zucker rats at 5 mg·kg (i.v.). In this study, which confirms that HFD groups have increased liver size and weight, CGA-7 Complex shows a significant reduction in liver and other adipose tissue weights when given orally at 100 mg/kg and 150 mg/kg compared to GCBE. CGA-7 Complex reduced serum cholesterol, triglyceride and glucose levels markedly and improved HDL levels compared to the GCBE treated group.

Conclusion

CGA-7 Complex is superior to coffee bean extract in obesity management. CGA-7 Complex reduced 25.3% and 26.4% in body weight gain at 100 mg/kg and 150 mg/kg respectively. CGA-7 Complex also demonstrated an ability to reduce serum cholesterol, triglyceride and glucose levels, and reduce fat accumulation in liver and reduce brown and white adipose tissue. CGA-7 Complex also improved serum HDL levels.

Example 6—Molecular Docking Studies of CGA-7 Complex with Fat Mass and Obesity Associated Protein (LTO) INTRODUCTION

Weight gain and obesity are major risk factors for conditions and diseases ranging from insulin resistance and type 2 diabetes mellitus to atherosclerosis and the sequelae of nonalcoholic fatty liver disease (Shoelson et al., 2007). Physiologically, obesity is a disarray of energy balance and primarily considered as a disorder of lipid metabolism (Strader et al., 1998). The condition is associated with a growing number of enzymes involved in lipid metabolic pathways. They represent a rich pool of potential therapeutic targets for obesity (Shi & Burn, 2004; Melnikova & Wages, 2006). Fat mass and obesity associated protein also known as alpha-ketoglutarate-dependent dioxygenase (FTO) is an enzyme that appears to be correlated with obesity in humans (Frayling et al., 2007). FTO contributes to the regulation of the global metabolic rate, energy expenditure and energy homeostasis. FTO contributes to the regulation of body size and body fat accumulation.

Green coffee bean extract has been reported to have potent antiobesity and hypoglyceridemic properties by in vivo studies. Chlorogenic acids are a major group of polyphenols found in raw green coffee bean and contribute significantly to the pharmacological efficacy of coffee bean extract. The objective of the present study was to explore the in silico anti-obesity activity of CGA-7 Complex from green coffee bean extract by targeting FTO.

Materials and Methods

AutoDock tools were utilized to generate grids, calculate dock score and evaluate the conformers of inhibitors bound in the active site of AMPK as targets for antidiabetic activity. Automated docking is a graphical user interface. AutoDock 4.2 was employed to get docking and binding scores; which were implemented by Lamarckian genetic algorithm method. The ligand molecules i.e., the seven isomers of chlorogenic acid (FIG. 1) and Orlistat were designed and the structure was analyzed using ACD/Chemsketch. The PRODRG server was used to minimize energy of drug compounds and 3D coordinates were prepared. The protein structure file (PDB ID: 3LFM) (FIG. 2) was taken from PDB and was edited by removing the hetero atoms using Python molecule viewer. The grid map was centered at particular residues of the protein and was generated with AutoGrid. As per genetic algorithm all the torsions were allowed to rotate during docking. The Lamarckian genetic algorithm and the pseudo-Solis and Wets methods were applied for minimization, using default parameters (Rodriguez and Infante, 2011).

Results

All the seven isoforms of chlorogenic acid in CGA-7 Complex binds very efficiently within the active pocket of FTO (FIG. 3). The result obtained is comparable to orientation of standard drug Orlistat. The binding energy required is less than that of Orlistat and the firm binding of isoforms is evident from the formation of more hydrogen bonds of ligand molecules in comparison with standard drug (Table 1).

TABLE 18 Molecular docking results of fat mass and obesity associated protein Thermodynamic parameters Binding Ligand H- Molecule energy efficiency bonds Interactions 3-O-Caffeoylquinic −8.04 −0.32 1.28 −11.32 5 Leu78 acid His73 Arg80 Gln468 4-O-Caffeoylquinic −7.01 −0.28 7.21 −10.3 7 Leu78 acid Lys391 Asp467 Arg80 5-O-Caffeoylquinic −7.43 −0.3 3.56 −10.7 6 Arg80 acid Leu78 His73 Arg80 Gln468 5-O-Feruloylquinic −5.56 −0.21 84.65 −8.84 5 His73 acid Arg80 Gln468 Leu78 3,4-O- −5.32 −0.21 126.75 −8.6 4 His73 Dicaffeoylquinic acid Gln468 Arg80 3,5-O- −5.88 −0.16 48.78 −10.95 6 Asp208 Dicaffeoylquinic acid His73 Gln468 Lys74 Lys391 4,5-O- −7.73 −0.26 2.14 −12.81 5 Arg80 Dicaffeoylquinic acid Leu78 Lys391 His73 Orlistat (Std) −4.65 −0.14 390.87 −11.21 3 Ser95 Arg80

Conclusion

CGA-7 Complex is a mixture of 7 isoforms of chlorogenic acid from green coffee bean extract and is effective in interacting with fat mass and obesity associated protein (FTO) more efficiently than the standard drug Orlistat and hence may serve as a better candidate for the development of anti-obesity drugs in future.

The embodiments herein and the various features and advantageous details thereof are explained with reference to the non-limiting embodiments in the description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skill in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein.

The foregoing description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein.

Any discussion of documents, acts, materials, devices, articles and the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application.

While considerable emphasis has been placed herein on the particular features of this disclosure, it will be appreciated that various modifications can be made, and that many changes can be made in the preferred embodiments without departing from the principles of the disclosure. These and other modifications in the nature of the disclosure or the preferred embodiments will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.

The disclosures of all references mentioned in this application are incorporated by reference in their entirety as if set forth verbatim herein.

REFERENCES

-   1. Brown J P. A review of the genetic effect of occurring     flavonoids, anthraquinones and related compounds. Mutat Res 1980;     75(3):243-277. -   2. Farnsworth N R, Akerele O, Bingel A S, Soejarto D D, Guo Z.     Medicinal plants in therapy. Bull World Health Organ. 1985;     63(6):965-81. -   3. Jovtchev G, Stergios M, Schubert I. A comparison of     N-methyl-N-nitrosourea induced chromatid aberrations and micronuclei     in barley meristems using FISH techniques. Mutat Res 2002;     517:47-51. -   4. Kamboj V P. Herbal Medicine. Curr Sc 2000; 78(1):35-37. -   5. OECD Guideline for the testing of chemicals-Repeated Dose 90-day     Oral Toxicity Study in Rodents; TG 408, 21^(st) September 1998. -   6. OECD Guideline No. 420, “Acute Oral Toxicity”—Fixed Dose     Procedure 17^(th) December 2001. -   7. Sultan A O, çelik T A. Genotoxic and antimutagenic effects of     Capparis spinosa L. on the Allium cepa L. root tip meristem cells.     Caryologia, 2009; 262: 114-123. -   8. Song S. J., Choi S., Park T. (2014) Decaffeinated Green Coffee     Bean Extract Attenuates Diet-Induced Obesity and Insulin Resistance     in Mice. Evidence-Based Complementary and Alternative Medicine,     1-14. -   9. Vongsak B., Sithisarn P., Gritsanapan W. (2013) Simultaneous     Determination of Crypto-Chlorogenic Acid, Isoquercetin, and     Astragalin Contents in Moringa oleifera Leaf Extracts by     TLC-Densitometric Method. Evidence-Based Complementary and     Alternative Medicine, 1-7. -   10. Narita Y., Inouye K. (2013) Degradation Kinetics of Chlorogenic     Acid at Various pH Values and Effects of Ascorbic Acid and     Epigallocatechin Gallate on Its Stability under Alkaline     Conditions. J. Agric. Food Chem., 61 (4), 966-972. -   11. Farah A., Paulis T. D., Martin P. R., Trugo L. C. (2005) Effect     of Roasting on the Formation of Chlorogenic Acid Lactones in     Coffee. J. Agric. Food Chem., 53, 1505-1513. -   12. Sarojini B K, Vidyagayatri M, Darshanraj C G, Bharath B R,     Manjunatha H, DPPH scavenging assay of novel     1,3-disubstituted-1H-pyrazol-5-ols and their in silico studies on     some proteins involved in Alzheimer's disease signaling cascade.     Letters in Drug Design & Discovery, 2011, 7, 214-224 -   13. Blois M S. Antioxidant determinations by the use of a stable     free radical. Nature 1958; 26: 1199-1200 -   14. Nishikimi M, Appaji N, Yagi K, The occurrence of superoxide     anion in the reaction of reduced phenazine methosulfate and     molecular oxygen, Biochemical and Biophysical Research     Communications, 1972, 46, 849-854 -   15. Oyaizu M, Studies on product of browning reaction prepared from     glucose amine. Japan Journal of Nutrition, 1986, 44, 307-315 -   16. Prieto P, Pineda M and Aguilar M. Spectrophotometric     quantitation of antioxidant capacity through the formation of a     Phosphomolybdenum Complex: Specific application to the determination     of vitamin E. Analytical Biochemistry, 1999, 269, 337-341. -   17. Frayling T M, Timpson N J, Weedon M N, Zeggini E, Freathy R M,     Lindgren C M, Perry J R, Elliott K S, Lango H, Rayner N W, Shields     B, Harries L W, Barrett J C, Ellard S, Groves C J, Knight B, Patch A     M, Ness A R, Ebrahim S, Lawlor D A, Ring S M, Ben-Shlomo Y, Jarvelin     M R, Sovio U, Bennett A J, Melzer D, Ferrucci L, Loos R J, Barroso     I, Wareham N J, Karpe F, Owen K R, Cardon L R, Walker M, Hitman G A,     Palmer C N, Doney A S, Morris A D, Smith G D, Hattersley A T,     McCarthy M I (2007). A common variant in the FTO gene is associated     with body mass index and predisposes to childhood and adult obesity.     Science 316 (5826): 889-94. -   18. Melnikova I, Wages D (2006). Antiobesity therapies. Nature     Reviews Drug Discovery 5, 369-370. -   19. Rodriguez A, Infante D (2011). Characterization in silico of     flavonoids biosynthesis in Theobroma cacao L. Network Biology 1:     34-45. -   20. Shi Y, Burn P (2004). Lipid metabolic enzymes: emerging drug     targets for the treatment of obesity. Nature Reviews Drug Discovery     3: 695-710. -   21. Shoelson S E, Herrero L, Naaz A (2007). Obesity, inflammation     and insulin resistance, Gastroenterology 132(6): 2169-80. -   22. Strader C D, Hwa J J, Van Heek M, Parker E M (1998). Novel     molecular targets for the treatment of obesity. Drug Discovery Today     3: 250-256. 

1-25. (canceled)
 26. A method of modulating body weight, said method comprising: administering to a subject a composition comprising a mixture of chlorogenic acids, said mixture comprising 12.5% 3-caffeoylquinic acid (3-CQA), 46.9% 5-caffeoylquinic acid (5-CQA), 17.2% 4-caffeoylquinic acid (4-CQA), 4.6% 5-feruloylquinic acid (5-FQA), 6.2% 3,4 dicaffeoylquinic acid (3,4 di CQA), 4.6% 3,5 dicaffeoylquinic acid (3,5 di CQA), and 8.0% 4,5 dicaffeoylquinic acid (4,5 di CQA); wherein administering said composition modulates body weight in said subject.
 27. The method of claim 26, wherein administering said composition reduces body weight in said subject.
 28. The method of claim 26, wherein administering said composition prevents an increase in body weight in said subject.
 29. The method of claim 26, wherein administering said composition reduces body fat in said subject.
 30. The method of claim 26, wherein administering said composition prevents an increase in body fat in said subject.
 31. The method of claim 26, wherein administering said composition reduces at least one of waist circumference and hip circumference in said subject.
 32. The method of claim 26, wherein administering said composition reduces triglycerides in said subject, reduces cholesterol in said subject, increases high density lipids in said subject, reduces low density lipoprotein in said subject, reduces very low density lipoprotein in said subject, or combinations thereof.
 33. The method of claim 26, wherein said subject is overweight.
 34. The method of claim 26, wherein said subject is obese.
 35. The method of claim 26, wherein said subject has a healthy body weight.
 36. The method of claim 26, wherein said mixture of chlorogenic acids is obtained from coffee beans.
 37. The method of claim 36, wherein said coffee beans are green coffee beans dried coffee beans, or a combination thereof.
 38. The method of claim 36, wherein said coffee beans are coffea Arabica coffee beans.
 39. The method of claim 36, wherein said coffee beans comprise coffee bean pulp.
 40. The method of claim 26, wherein said composition is administered orally to said subject.
 41. The method of claim 26, wherein said composition comprises a pharmaceutically acceptable excipient.
 42. The method of claim 26, wherein said composition comprises about 20% to 60% w/w chlorogenic acid.
 43. The method of claim 26, wherein said composition is in the form of a powder, pill, tablet, pellet, granule, capsule, thin film, solution, spray, syrup, linctus, lozenge, pastille, chewing gum, paste, vapor, suspension, emulsion, ointment, cream, lotion, liniment, gel, drop, topical patch, buccal patch or injection.
 44. The method of claim 26, wherein said composition is a liposomal formulation.
 45. The method of claim 26, wherein said subject is a human. 